Affordable Access

deepdyve-link
Publisher Website

Feasibility of 320-row multi-detector computed tomography angiography to assess bioabsorbable everolimus-eluting vascular scaffolds.

Authors
  • Asami, Masahiko1
  • Aoki, Jiro1
  • Serruys, Patrick W2
  • Abizaid, Alexandre3
  • Saito, Shigeru4
  • Onuma, Yoshinobu2
  • Kimura, Takeshi5
  • Simonton, Charles A6
  • Tanabe, Kengo7
  • 1 Division of Cardiology, Mitsui Memorial Hospital, 1 Kanda-Izumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan. , (Japan)
  • 2 Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands. , (Netherlands)
  • 3 Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. , (Brazil)
  • 4 Department of Cardiology, Shonan Kamakura General Hospital, Kanagawa, Japan. , (Japan)
  • 5 Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. , (Japan)
  • 6 Abbott Vascular, Santa Clara, CA, USA.
  • 7 Division of Cardiology, Mitsui Memorial Hospital, 1 Kanda-Izumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan. [email protected] , (Japan)
Type
Published Article
Journal
Cardiovascular intervention and therapeutics
Publication Date
Apr 01, 2016
Volume
31
Issue
2
Pages
96–100
Identifiers
DOI: 10.1007/s12928-015-0353-1
PMID: 26445951
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Coronary computer tomographic angiography (CCTA) for screening intra-arterial vessel disease is gaining rapid clinical acceptance in recent years, but its use for such assessments in metal-stented vessel segments is very limited due to blooming artifacts introduced by the metal. However, vessel segments treated by the polymeric everolimus-eluting bioresorbable vascular scaffolds (Absorb) are readily monitored for intravascular disease over time with CCTA. The data on the accuracy of multi-detector computed tomography (MDCT) in patients treated with Absorb is still sparse. Results on 5 Japanese case studies from ABSORB EXTEND are presented here. Five patients were treated with Absorb, and follow-up angiography was conducted at 8 to 14 months as per routine site standard of practice. 320-row MDCT scan was performed within 1 month before the angiography. By MDCT, all Absorb-treated lesions were clearly evaluated and restenosis were not observed. Minimal diameter and % diameter stenosis were similar between MDCT and quantitative angiography (2.07 ± 0.13 vs. 2.03 ± 0.06 mm, P = 0.86, and 22.5 ± 5.0 vs. 21.5 ± 4.5 %, P = 0.88, respectively). MDCT appears to be feasible and useful for evaluating lumen patency and vessel disease in segments implanted with Absorb at follow-up.

Report this publication

Statistics

Seen <100 times